Table 1 List of drugs undergoing clinical trials in MPN
NCT Number | Drugs | Target | Phase | Status |
|---|---|---|---|---|
NCT03895112 | AVID200 | TGF-β1 and TGF-β3 | Phase 1 | Recruiting |
NCT03566446 | CALRLong 36 peptide | CALR | Phase 1 | Active, not recruiting |
NCT03144687 | Itacitinib, Ruxolitinib | JAK | Phase 2 | Recruiting |
NCT03075826 | SGI-110 | DNMT | Phase 2 | Recruiting |
NCT03065400 | Pembrolizumab | PD-1 | Phase 2 | Recruiting |
NCT02718300 | Parsaclisib, Ruxolitinib | PI3Kδ, JAK | Phase 2 | Recruiting |
NCT02493530 | TGR-1202, Ruxolitinib | PI3Kδ, JAK | Phase 1 | Recruiting |
NCT02407080 | RG7388, Pegasys | MDM2 | Phase 1 | Active, not recruiting |
NCT02268253 | SL-401 | CD123 | Phase1/2 | Recruiting |
NCT02257138 | Decitabine, Ruxolitinib Phosphate | DNMT, JAK | Phase 1/2 | Recruiting |
NCT01761968 | Givinostat | HDAC | Phase 2 | Recruiting |
NCT01633372 | Itacitinib | JAK1 | Phase 2 | Active, not recruiting |
NCT01594723 | LY2784544 | JAK | Phase 2 | Active, not recruiting |
NCT01393509 | PU-H71 | Hsp90 | Phase 1 | Active, not recruiting |